Pharmacology and psychoactive substances – Page 4
-
FeatureNew opioid drugs
Creating powerful new painkillers is a constant battle against side-effects – particularly addictions. James Mitchell Crow reports
-
OpinionRestarting the mental health pipeline
The lack of UK investment in new drugs for mental health disorders is a problem – but the tide may be about to turn
-
CareersThe trials and tribulations of drug discovery
The many pitfalls medicinal chemists face when creating a new drug
-
-
OpinionWe need a global plan to beat resistance
We all need to do our bit and act for the common good if we’re going to protect antibiotics
-
OpinionCan we wait for e-cigarette trials?
Safety data is needed but is not a reason to ignore vaping now, says Thomas Hartung
-
OpinionRethinking risk assessment
Toxicologists must embrace better ways of accounting for low dose effects, argue Annamaria Colacci and Nicole Kleinstreuer
-
BusinessAdvancing animal testing alternatives
Animal rights groups are engaging with researchers and regulators to develop replacement tests and ensure they’re adopted
-
-
PodcastBarbituric acid
It may have been largely superceded in the clinic but Phil Robinson discovers there is no rest yet for barbituric acid
-
OpinionA large life, fully lived
Carl Djerassi leaves many legacies besides the contraceptive pill,says Mark Peplow
-
OpinionTarget ignorance to tackle resistance
Countries like India are bearing the brunt of antibiotic resistance, and education could be a key tool in tackling its spread
-
-
PodcastCannabicyclohexanol
Used to make synthetic cannabis, cannabicyclohexanol may be more risky than its non-synthetic counterpart
-
-
-
PodcastPsilocybin & Mescaline
Simon Cotton explores our hallucinogenic horizons with psilocybin and mescaline
-
-
-
PodcastMagnesium oxide
You may have created it in a fiery flash or taken it to soothe a burning stomach. Simon Cotton on magnesium oxide